Skip to main content
. Author manuscript; available in PMC: 2015 Dec 15.
Published in final edited form as: Biol Psychiatry. 2014 Apr 12;76(12):953–962. doi: 10.1016/j.biopsych.2014.04.003

Figure 4. Low-dose MPH potentiates NMDAR-EPSC via norepinephrine reuptake inhibition and adrenergic receptor activation.

Figure 4

(A, B) Summarized input-output curves of NMDAR-EPSC in PFC pyramidal neurons from rats treated with saline, Maprotiline (A, 20 mg/kg, i.p.), or GBR-12909 (B, 5 mg/kg, i.p.). Inset: representative traces of NMDAR-EPSC. Scale bar: 50 pA, 200 ms. **: p < 0.01. (C) Summarized input-output curves of NMDAR-EPSC in saline- vs. MPH- (0.5 mg/kg, i.p.) injected rats pre-treated with prazosin and yohimbine (Prazosin, 1 mg/kg, Yohimbine, 5 mg/kg, i.p., injected 0.5 hr before MPH injection). Inset: representative NMDAR-EPSC traces. Scale bar: 50 pA, 100 ms. (D) Summarized input-output curves of NMDAR-EPSC in saline- vs. MPH-injected rats pre-treated with SCH23390 and sulpiride (SCH23390, 1 mg/kg, sulpiride, 50 mg/kg, i.p., injected 0.5 hr before MPH injection). Inset: representative traces. Scale bar: 50 pA, 100 ms. **: p < 0.01.